Use of bcl6 inhibitors for treating autoimmune diseases

Abstract

The present invention provides a method of treatment of an autoimmune disease, comprising administering an effective amount of a BCL6 inhibitor to an individual in need thereof.

1 . A method for inhibiting or stopping abnormal Tfh activity in individuals suffering from an autoimmune disease, comprising administering to an individual in need of such treatment an effective amount of a BCL6 inhibitor. 
     
     
         2 . The method of  claim 1 , wherein the autoimmune disease is selected from the group consisting of lupus erythematosus, ankylosing spondylitis, Chagas disease, chronic obstructive pulmonary disease, Crohns Disease, dermatomyositis, diabetes mellitus type 1, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, idiopathic thrombocytopenic purpura, interstitial cystitis, mixed connective tissue disease, morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, schizophrenia, scleroderma, Sjögren's syndrome, stiff person syndrome, temporal arteritis, ulcerative colitis, vasculitis, vitiligo, Wegener's granulomatosis, and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the autoimmune disease is lupus erythematosus. 
     
     
         4 . The method of  claim 1 , wherein said BCL6 inhibitor is a peptide or non-peptide inhibitor. 
     
     
         5 . The method of  claim 4 , wherein said peptide inhibitor is a BPI. 
     
     
         6 . The method of  claim 5 , wherein the BPI is BPI-1. 
     
     
         7 . The method of  claim 1 , wherein the BCL6 inhibitor is a molecule of formula Compound 1. 
     
     
         8 . The method of  claim 1 , wherein the BCL6 inhibitor is molecule 79-6. 
     
     
         9 . The method of  claim 1  wherein said BCL6 inhibitor is administered once daily to said individual in an amount of about 0.05 mg/kg to about 50 mg/kg. 
     
     
         10 . A method of treatment of an autoimmune disease in an individual in need thereof, comprising administering an effective amount of a BCL6 inhibitor to inhibit non-specific stimulation of B cells thereby ameliorating autoimmune disease symptoms in the individual. 
     
     
         11 . The method of  claim 10  wherein said BCL6 inhibitor is a peptide or non-peptide inhibitor. 
     
     
         12 . The method of  claim 11  wherein said peptide inhibitor is BPI-1. 
     
     
         13 . The method of  claim 10 , wherein the BCL6 inhibitor is a molecule of formula Compound 1. 
     
     
         14 . The method of  claim 10  wherein said BCL6 inhibitor is molecule 79-6. 
     
     
         15 . The method of  claim 10  wherein said BCL6 inhibitor is administered once daily to said individual in an amount of about 0.05 mg/kg to about 50 mg/kg. 
     
     
         16 . The method of  claim 10  wherein said treatment results in reduced secretion of auto-antibodies by B cells in said individual. 
     
     
         17 . The method of  claim 10  further comprising the step of assessing treatment efficacy by detecting the level of one or more autoantibodies in blood from said individual before and after said treatment ensues. 
     
     
         18 . The method of  claim 10  wherein the autoimmune disease is selected from lupus erythematosus, ankylosing spondylitis, Chagas disease, chronic obstructive pulmonary disease, Crohns Disease, dermatomyositis, diabetes mellitus type 1, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, idiopathic thrombocytopenic purpura, interstitial cystitis, mixed connective tissue disease, morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, schizophrenia, scleroderma, Sjögren's syndrome, stiff person syndrome, temporal arteritis, ulcerative colitis, vasculitis, vitiligo, Wegener's granulomatosis, and combinations thereof. 
     
     
         19 . The method of  claim 10  wherein the autoimmune disease is lupus erythematosus. 
     
     
         20 . A method of treatment of an autoimmune disease, comprising administering an effective amount of a BCL6 inhibitor to an individual in need thereof.